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Abstract
Seventy-eight melanoma patients and 10 healthy individuals were examined. Follow-up 
examinations of all melanoma patients were performed regularly every three months. Myeloid-
derived suppressor cells (MDSC) were defined as lineage negative (CD3−, CD19−, CD56−),  
HLA-DR−/low, CD11b+ and CD33+. Classification of granulocytic (GrMDSC) and monocytic (MoMDSC) 
subsets was based on the CD15 and CD14 expression, respectively. Unlike the MoMDSC, that 
were present in 60% of healthy controls and 15% of melanoma patients, the GrMDSC were 
present in all examined participants, and the melanoma patients were found to have statistically 
higher frequencies compared with healthy controls. Accordingly, we kept focused on GrMDSC 
frequencies in relation to the melanoma stages and course of the disease. The GrMDSC values 
are highest in stage IV melanoma patients, with statistical significance compared with stages IA, 
IB, IIA and IIB. Patients with progression had statistically higher GrMDSC counts comparing with 
those with stable disease (P = 0.0079). Patients who had progression-free interval (PFI)  
< 12 months showed significantly higher GrMDSC values compared with those with PFI > 
12 months (P = 0.0333). GrMDSC showed significant negative correlation with PFI intervals 
(P = 0.0095). The GrMDSC subset was predominant in all our patients. We confirmed that 
GrMDSC do accumulate early in the peripheral blood of melanoma patients and their frequencies 
correlate narrowly with the clinical stage and the spread of the disease. The increase in GrMDSC 
frequencies correlates well with a progressive disease and could be considered a potential 
predictive biomarker of high-risk melanoma cases that are more likely to have a shorter PFI.
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Introduction
The presence of suppressor cells of myeloid origin in tumor-
bearing mice was identified in the late 1980s (1). The inter-
est in these cells was renewed by Bronte et al. who shed a 
new light on the suppression of the CD8+ T-cell responses (2). 
There is sufficient evidence that myeloid-derived suppressor 
cells (MDSC) are present in cancer patients and that their 
immunosuppressive activities undoubtedly contribute to the 
tumor progression (3).
Immature myeloid cells with the same phenotype as MDSC 
are continually generated in the bone marrow of healthy indi-
viduals and they differentiate into mature myeloid cells with-
out causing detectable immunosuppression. Neoplastic cells 
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condition distant sites, such as the bone marrow and spleen, 
by releasing soluble factors that drive the accumulation of 
highly immunosuppressive immature myeloid cells within the 
tumor as well as dendritic cells, macrophages and granulo-
cytes with immunosuppressive function in the tumor (4).
MDSC research is ongoing in several areas: their role in 
tumor progression, in the prognosis of survival, in the predic-
tion of response to therapy and finally, their use for targeted 
anti-cancer immunotherapy.
The immunophenotyping and counting of MDSC is a 
challenging task because of their heterogeneity and the 
absence of MDSC-specific markers. On the basis of the 
expression of Gr-1 and CD11b in mice, MDSC can be sub-
divided into at least six different subsets (5). The two most 
relevant subsets are granulocytic MDSC (GrMDSC) and 
monocytic MDSC (MoMDSC). The GrMDSC subset is rec-
ognized as CD11b+Gr-1highLy6G+Ly6Clow/int and the MoMDSC 
as CD11b+Gr-1intLy6G-Ly6Chigh (5). Similar to the mice, there 
are two major subtypes of MDSCs in humans, granulocytic 
MDSC (CD11b+CD14-CD15+CD16lowCD33+CD66b+CD124+) 
and monocytic MDSC (CD11b+CD14+CD15+/−CD16−CD33+
CD66b+/−CD124+) (3).
Different MDSC subsets are detected in different cancer 
types; however, it is little known whether any particular subset 
is predominant. Various researchers are currently questioning 
whether the cancer type influences the subset of these cells 
or whether this is a result of different markers being used (3).
There are only a few studies on MDSC and clinical outcome 
in melanoma patients (6–8). The aim of our study was to iden-
tify the predominant subset of MDSC in melanoma patients 
and to evaluate if it relates to clinical course of melanoma dis-
ease. We found significant accumulation of a subpopulation 
of granulocytes that may correspond to granulocytic MDSC 
and the acronym GrMDSC in the following text refers to this 
subpopulation.
Methods
Patients and healthy controls
Seventy-eight melanoma patients and 10 healthy individu-
als as a control group were recruited during October and 
November in 2012 from the Clinics of Dermatovenerology 
and Plastic Surgery, the Military Medical Academy, Belgrade, 
Serbia. The patients and healthy controls consented to this 
research, which was approved by the local Research Ethics 
Committee. The experimental group of melanoma patients 
and control group were matched for sex and age.
Recorded parameters
The seventh edition of the American Joint Committee on 
Cancer (AJCC) and TNM melanoma staging and classifica-
tion were used. The follow-up examinations of all melanoma 
patients were performed regularly every three months. Various 
parameters were obtained from clinical and dermoscopic 
examination, laboratory blood tests (complete and differen-
tial blood-cell count, general biochemical analyses, LDH and 
S100A protein), an ultrasound of regional lymph nodes, radio-
graphic imaging and periodic multislice computed tomogra-
phy imaging. The progression-free interval (PFI) was defined 
as the time from the first diagnosis to the time of tumor pro-
gression into a higher stage and was expressed in months.
Samples
Three to six milliliters of venous blood were collected from 
the melanoma patients and healthy controls and erythro-
cytes were removed using the lysing buffer (EDTA, NH4Cl, 
KHCO3) for 10 min with constant mixing. The remaining nucle-
ated cells were washed out twice in the RPMI 1640 culture 
medium with 5% of normal human serum, centrifuged and re-
suspended. Separation of PBMC for the comparative analysis 
was performed using Lymphocyte Separation Medium LSM 
1077. The separation process was performed by centrifuga-
tion at 1.200  × g for 20 min. The interphase layer between 
the plasma and the separation solution was extracted with 
a Pasteur pipette and washed twice in culture medium. The 
cell counting was done manually, in an improved Neubauer 
chamber, and automatically, using the Beckman Coulter ACT 
differ blood counter. Finally, the suspension with 1 × 106 cells 
per 100 µl was aliquoted in 12 × 75 mm test tubes for further 
immunostaining.
Neutrophil/lymphocyte ratio calculation
Complete and differential blood counts in the peripheral 
blood samples were done on the Beckman Coulter ACT differ 
blood counter and the neutrophil/lymphocyte ratio (NLR) was 
calculated by dividing the neutrophil count by the lymphocyte 
count.
Immunophenotyping of cells
The following antihuman mAbs were used in different com-
binations for multicolor analysis of the fresh peripheral 
blood samples: CD15-FITC and PECy7, CD33-PE and 
PECy7, CD45-ECD, HLA-DR PE/Cy5, CD14-FITC, CD16-PE, 
CD11b-PE, CD10-PECy7, CD3-FITC, CD19-FITC and CD56-
FITC (Beckman Coulter, USA). The flow cytometry was per-
formed using a Beckman Coulter FC 500 flow cytometer 
with CXP analysis software. MDSC were defined as lineage 
negative (CD3−, CD19−, CD56−), HLA-DR−/low, CD11b+ and 
CD33low. The MDSC were initially gated based on a CD11b 
versus HLA-DR dot plot. The HLA-DR−/low and CD11b+ cells 
were further analyzed for the lineage markers (CD3, CD19 
and CD56), as well as CD10, CD14, CD15, CD16 and CD45. 
The classification of granulocytic and monocytic subsets was 
based on the CD15 and CD14 expression, respectively. The 
GrMDSC were separated from the mature granulocyte popu-
lation on the basis of CD10 negativity, lower and inhomoge-
neous expression of virtually all positive markers (CD11b, 
CD15, CD16, CD33 and CD45) and lower positioning on the 
CD45 versus Side Scatter (SS) dot plot. The MDSC frequency 
was expressed as a percentage of these cells out of all nucle-
ated cells.
Statistical analysis
Data analysis was performed using the GraphPad Prism 5 soft-
ware. Depending on the normality of data, the following tests 
were used: the Student’s t-test, the Mann–Whitney test, the 
one-way ANOVA test and the nonparametric Kruskal–Wallis 
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test. To assess the strength of association between obtained 
values, we used the Pearson’s and Spearman’s correlation 
tests.
Results
Immunophenotype and subsets of the MDSC in melanoma 
patients and healthy controls
The MDSC frequencies were determined in 78 melanoma 
patients and 10 healthy controls (Fig. 1). The detected immu-
nophenotype of the targeted MDSC populations is given in 
Table 1.
GrMDSC and MoMDSC subsets were identified according 
to the expression of CD15 and CD14, respectively, within the 
HLA-DR−/lowCD11b+CD33lowLin− population. We found that the 
MoMDSC subset was present in only 60% of healthy controls 
and 15% of our melanoma patients (Table 2). Furthermore, 
MoMDSC were absent in all melanoma patients in stage IIIC 
and stage IV. On the contrary, we found that the GrMDSC 
subset was present in the peripheral blood of all melanoma 
patients and all healthy controls; therefore, we decided to 
focus on this particular subset only.
Comparative analysis of GrMDSC in lysed 
peripheral blood samples to GrMDSC in 
density-gradient-separated PBMC
In the pilot study including six melanoma patients, we per-
formed comparative analysis of GrMDSC detected in lysed 
peripheral blood samples to GrMDSC obtained in the PBMC 
fraction separated on a density gradient. We found that 
HLA-DR−/lowCD10−CD11b+CD14−CD15+CD16low/intCD33lowCD-
45lowLin− cells copurified with the PBMC on density gradient 
and their counts correlated positively with the cells of the 
same phenotype found in lysed peripheral blood samples 
(Pearson r = 0.9964, P < 0.0001, data not shown).
Phenotypic differences between the GrMDSC and mature 
granulocytes
With the exception of CD10, which was negative on GrMDSC 
(Fig. 2A), the GrMDSC and mature granulocyte populations 
were positive for the same examined markers but with major 
differences in intensity level and homogeneity of expression. 
As expected by their immature state, the GrMDSC expressed 
low levels of CD45—common leukocyte antigen. In virtu-
ally all patients, the GrMDSC population was positioned in a 
region with the lowest CD45 intensity level and lower SS rela-
tive to mature granulocytes on the CD45 versus SS dot plots 
(Fig.  2B). Comparison of the SS average values between 
the GrMDSC and mature granulocytes showed significantly 
lower SS positioning of the GrMDSC (59.8 ± 1.3 versus 
97.7 ± 3.7, P < 0.0001, Fig. 2C). All the positive markers on 
the GrMDSC population (CD11b, CD15, CD16, CD33, CD45) 
showed inhomogeneous and lower expression relative to 
mature granulocytes. Only the CD15 expression could reach 
the expression intensity of mature granulocytes in the sub-
stantial part of GrMDSC (Fig.  2D–H). Comparison of mean 
fluorescence intensity average values between GrMDSC and 
mature granulocytes confirmed lower expression on GrMDSC 
for all examined markers (Fig. 2I).
The GrMDSC frequencies correlate inversely with the 
frequencies of mature granulocytes without significant 
elevation of NLR in the peripheral blood
The GrMDSC frequencies in the peripheral blood of the 
melanoma patients correlated inversely with the frequen-
cies of mature granulocytes with high statistical significance 
(Pearson r = −0.5709, P < 0.0001, data not shown). There 
was no such correlation between the GrMDSC and mature 
granulocytes in the peripheral blood of healthy individuals.
The average NLR in the peripheral blood of the melanoma 
patients was slightly higher compared with healthy controls, but 
statistical significance could not be reached (1.9 ± 0.2 versus 
1.7 ± 0.2, P = 0.7368, data not shown).
The GrMDSC frequencies are elevated in the peripheral blood 
of melanoma patients when compared with the control group
Regardless of clinical and pathohistological stage, the 
GrMDSC frequencies were significantly higher in the samples 
of melanoma patients than in the healthy controls (8.2 ± 0.7 
versus 0.9 ± 0.07, P < 0.0001, Fig. 3A). This significant differ-
ence was further confirmed after the classification of patients 
according to TNM or AJCC criteria. The patients from all TNM 
stages (Fig. 3B) and all AJCC stages (Fig. 4A) had signifi-
cantly higher GrMDSC frequencies than healthy controls.
The GrMDSC frequencies correlate well with the clinical 
stage of melanoma
The GrMDSC frequencies are the highest in stage IV mela-
noma patients, significantly higher in stage IV than in stages 
IA, IB, IIA and IIB (Fig.  4B). Interestingly, the patients with 
melanoma stages IIC, IIIA, IIIB and IIIC, all at high risk for the 
development of distant metastases, showed no statistically 
significant differences in the GrMDSC frequencies compared 
to patients with melanoma stage IV.
The GrMDSC frequencies correlate well with melanoma 
progression
Eighteen out of 78 patients (23%) had a melanoma pro-
gression. Patients with progression had significantly higher 
frequencies of GrMDSC comparing to those with a stable dis-
ease (11.7 ± 2.0 versus 7.4 ± 0.6, P = 0.0079, Fig. 5A).
Negative correlation between GrMDSC frequencies and PFI
Patients with the progression of melanoma were classified 
into two groups depending on the length of time measured in 
months. A cut-off value of 12 months was used. The patients 
who had PFI < 12  months (n  =  8) showed significantly 
higher GrMDSC frequencies compared to those with PFI > 
12 months (n = 10) (15.9 ± 3.1 versus 7.9 ± 1.8, P = 0.0333, 
Fig.  5B). In addition, we found a significant negative cor-
relation between GrMDSC frequencies and PFI intervals 
(Spearman r = −0.6090, P = 0.0095, Fig. 5C).
Patients with metastatic melanoma have higher 
frequencies of GrMDSC in their peripheral blood than 
patients with localized disease
Melanoma patients were divided into two groups accord-
ing to the tumor stage when they were tested for MDSC. 
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The first group was composed of patients with localized 
disease in stages I and II (n = 60) and the second group 
was composed of patients with regional or distant metas-
tases in stages III and IV (n = 18). We found that patients 
with a very advanced metastatic disease had significantly 
higher frequencies of GrMDSC (11.6 ± 2.0 versus 7.0 ± 0.6, 
P  =  0.0032) compared to patients with localized disease 
(Fig. 6A).
The GrMDSC frequencies correlate well with the increase 
in the risk of developing distant metastases
We divided the patients without a distant metastatic dis-
ease according to their risk of developing distant metas-
tases into three groups: a low-risk group with melanoma 
stage IA, a medium-risk group with melanoma stages IB, 
IIA and IIB and a high-risk group with melanoma stages 
IIC, IIIA, IIIB and IIIC. The fourth group comprised patients 
with the metastatic disease stage IV. When the first three 
groups of melanoma patients without distant metastasis 
were compared with the fourth group of the patients in 
stage IV, we found that melanoma patients in stage IV 
had significantly higher frequencies of GrMDSC in com-
parison with the low-risk group (15.17 ± 3.260 versus 
5.678 ± 1.032, P  =  0.0062) and the medium-risk group 
(15.17 ± 3.260 versus 7.343 ± 0.6619, P = 0.0006). The dif-
ferences in the frequency of GrMDSC between stage IV 
melanoma patients and high-risk group were not statisti-
cally significant (Fig. 6B).
Fig. 1. Detection of GrMDSC by flow cytometry. Representative two-parameter dot plots showing identification of GrMDSC in lysed periph-
eral blood samples of melanoma patients (n = 78) stained for the indicated surface membrane markers. Quadrant regions were adjusted to 
the isotype control fluorescence. (A) On the HLA-DR versus CD11b dot plot ungated events are shown. Rectangular region R1 is plotted on 
HLAD−/CD11b+ events and represents the initial region in the detection process. The polygonal GrMDSC region within the R1 region paints 
the encompassed cells into black. Ellipses indicate positioning of the black-colored GrMDSC for easier tracking on the following dot plots. 
(B) The CD45 versus SS dot plot, gated on R1, shows CD45 positivity on black-colored cells. (C) The CD33 versus SS dot plot, gated on R1, 
shows black-colored cells positive, but with low expression of CD33. (D) The CD15 versus SS dot plot, gated on R1, shows strong expression 
of CD15 on black-colored cells. (E) The CD14 versus SS dot plot, gated on R1, shows black-colored cells negative for CD14 (#monoclonal 
antibodies conjugated with the same fluorochrome were examined in different tubes). (F) The CD16 versus SS dot plot shows positive, inho-
mogeneous expression of CD16 on black-colored cells (*the CD16 versus SS dot plot was gated on the R2 region drawn on the CD45 versus 
SS dot plot, in a different tube, and the black color is assigned on events on the CD45 versus SS dot plot, which was previously shown to be 
HLA-DR−CD11b+CD14−CD15+CD33low). The black-colored population was negative for CD3, CD19 and CD56 (data not shown).
Table 1. Immunophenotype of detected MDSC populations
MDSC subset HLA-DR CD10 CD11b CD14 CD15 CD16 CD33 CD45 CD3 CD19 CD56
GrMDSC −/low − + − + low/int low low − − −
MoMDSC −/low − + + − −/low low low − − −
Granulocytic (GrMDSC) and monocytic (MoMDSC) subsets were identified according to the expression of CD15 and CD14, respectively, within 
the HLA-DR−/lowCD11b+CD33lowLin− population.
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Discussion
Since previously published data on MDSC subsets in mela-
noma patients have not been clearly established and have 
been considered almost controversial, in this clinical study 
conducted on 78 melanoma patients, we tried to clarify the 
immunoprofile of particularly engaged MDSC subtypes in mel-
anoma patients. Although some authors reported MoMDSC 
to be the main subtype in melanoma patients (9–11), there is 
emerging evidence that GrMDSC are also present (12) and 
that both aforementioned subsets do co-exist in the same 
melanoma patient (12–14). We start our discussion emphasiz-
ing the importance of the blood sample handling during flow 
cytometric detection of the MDSC. As it turned out, different 
sample preparation methods (centrifugation on density gradi-
ent or lysis of erythrocytes) could be the important factor that 
influences interpretation of acquired results. On confirma-
tion of altered density of the targeted cells, we continued our 
study with lysed peripheral blood samples for several reasons: 
(i) to prevent possible loss of the granulocytic component of 
MDSC; (ii) to prevent possible changes in the expression of 
the surface membrane markers; (iii) to compare the MDSC fre-
quencies and phenotype with the rest of the leukocyte popula-
tions, including granulocytes; and (iv) to express the MDSC 
frequency as a percentage of total leukocytes.
By using fresh and lysed peripheral blood samples, we 
found the population of MDSC with the following immuno-
profile in all 78 melanoma patients recruited in this study: 
HLA-DR−/lowCD10−CD11b+CD14−CD15+CD16low/intCD33lowCD-
45lowLin−. This particular immunophenotype is compatible with 
the granulocytic subset of MDSC (15). Furthermore, in 12 out 
of 78 patients, we detected an additional MDSC subset with 
HLA-DR−/lowCD10−CD11b+CD14+CD15−CD16−/lowCD33lowCD-
45lowLin− immunophenotype, which is indicative of a mono-
cytic subset (15). Our substantial finding is attributable to the 
GrMDSC as a consistently present subset in all our examined 
melanoma patients. This differs from the data published by 
other authors (9, 11). In our opinion, this discrepancy in the 
reported subsets of MDSC could be due to two reasons. The 
first reason could be that in previous research, the MDSC were 
analyzed in the density-gradient-separated PBMC fraction, 
which could result in a partial loss of GrMDSC. The second 
one could be that previous researches were performed on 
cryopreserved blood samples, which could lead to the loss 
of temperature sensitive antigens. To our knowledge, a very 
few researchers used fresh and lysed peripheral blood sam-
ples (16, 17). Previously published data regarding MDSC in 
various mouse tumor models, including the mouse melanoma 
model specifically designed for the investigation of MDSC, 
showed that the predominant subset in the mouse melanoma 
is the GrMDSC subset (18–20). Dumitru et al. presented the 
data on peripheral blood GrMDSC in different human can-
cer types—including melanoma, but did not comment on 
whether GrMDSC is the dominant subset (21). We found that 
the GrMDSCs are not only present but also the predominant 
subset in melanoma patients.
Interestingly, we found that 10 out of 12 patients (83%) with 
detectable MoMDSC were in the earlier stages of melanoma 
(stages I and II). Only one patient in melanoma stage IIIA and 
one patient in stage IIIB had detectable MoMDSC but this same 
subset could not be detected in the peripheral blood of patients 
in melanoma stages IIIC and IV. This could be due to the fact 
that there were fewer patients with advanced melanoma stage 
in our study (stages III and IV), or perhaps, due to the change 
of the type of MDSC subset with the progression of the disease. 
Taking into account MDSC plasticity seen in mice (22), it is pos-
sible that various tumor-derived factors released in different mel-
anoma stages can cause differentiation into different subsets of 
MDSC (13). So far, the published data have shown high plastic-
ity of MDSC and the capability of these cells to transdifferentiate 
into antigen-presenting cells or into endothelium-like cells (23, 
24). The process of transdifferentiation means the change of one 
mature phenotype into another mature phenotype and is also 
known as phenotypic plasticity. The switching between a pro-
tumor and anti-tumor activity of the MDSC through the process 
of polarization and reprogramming of MDSCs was reported 
(25), but we could not find any publications regarding this 
direct conversion (transdifferentiation) between the GrMDSC 
and MoMDSC subsets. In our opinion, it would be interesting to 
investigate if there is a change in the predominant MDSC subset 
in the same patient with the progression of melanoma.
There are several mechanisms by which MDSC impair 
antitumor immunity in both an antigen-specific and an 
Table 2. Distribution of MDSC subsets in melanoma patients
Clinical stage GrMDSC MoMDSC
Number of patients Mean ± SEM Number of patients Mean ± SEM
% %
IA 10 5.7 ± 1.0 1 *
IB 25 7.4 ± 0.7 4 6.5 ± 1.5
IIA 13 7.4 ± 2.0 2 3.5 ± 0.5
IIB 7 6.9 ± 0.9 2 5.5 ± 0.5
IIC 5 9.0 ± 3.2 1 *
IIIA 4 8.6 ± 4.5 1 *
IIIB 4 9.0 ± 2.2 1 *
IIIC 4 11.8 ± 6.6 0 ND
IV 6 15.2 ± 3.3 0 ND
Controls 10 1.6 ± 0.7 6 0.4 ± 0.1
Average value of detected MDSC per stage (mean ± SEM). ND, not detected
 *Only one patient with detectable MoMDSC in the group.
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antigen-nonspecific manner (26–29). Some of the first studied 
and described are the high expression of arginase-1 (ARG1), 
production of reactive oxygen species (ROS) and production 
of nitric oxide (NO) (30). To date, the difference in the pro-
duction of ROS and NO between GrMDSC and MoMDSC is 
well established, wherein the GrMDSC express high levels 
of ROS and low levels of NO, whereas the MoMDSC express 
low levels of ROS and high levels of NO (18, 31). Both sub-
sets express high levels of ARG1 (18), although some authors 
showed that ARG1 is mainly expressed by GrMDSC (32, 33). 
Consequently, identification of the predominant MDSC subset 
in a given cancer patient could be of therapeutic importance 
because, by the analogy with mice models (34), different 
subsets of human MDSC could use different mechanisms 
to suppress T-cell function. Blockage of the specific mecha-
nism, using the proper agent such as synthetic triterpenoids 
that reduce ROS production in MDSC, or nitro-aspirin that 
inhibits inducible NO synthase, could improve effectiveness 
of anticancer immunotherapy (35).
On the basis of the fact that we found that only the GrMDSC 
subset was consistently present in the peripheral blood of all 
our melanoma patients and all healthy controls, we therefore 
decided to focus our research on this particular subset. It 
should be emphasized that the distinction between GrMDSC 
and activated granulocytes is a challenging task not only for 
immunophenotyping but also from a functional point of view, 
Fig. 2. Phenotypic differences between GrMDSC (black) and mature granulocytes (gray). (A) The CD10 versus SS dot plot, gated on the R1 
region (see Fig. 1A), shows CD10 positive mature granulocytes and black-colored GrMDSC negative for CD10 (marked with an ellipse). (B) On 
the CD45 versus SS dot plot, there is a noticeably lower positioning of the GrMDSC on the SS axis, as well as lower CD45 expression relative 
to mature granulocytes. (C) Bar graph shows the result of the comparison of SS average values between GrMDSC (black) and mature granulo-
cytes (gray) confirming significantly lower SS positioning of the GrMDSC compared with mature granulocytes. Mean values of 78 measurements 
were compared using Mann–Whitney test. (D–H) Overlay histograms of indicated markers showing different pattern and intensity of expres-
sion on GrMDSC (black) relative to mature granulocytes (gray). All the surface membrane markers found to be positive on both populations, 
the GrMDSC and the mature granulocytes, showed lower and inhomogeneous expression on the GrMDSC. (I) Bar graph showing results of 
the comparison of mean fluorescence intensity (MFI) between GrMDSC (black) and mature granulocytes (gray), confirming significantly lower 
expression of indicated markers on the GrMDSC population. Mean values of 78 measurements were compared using Mann–Whitney test. *The 
bars showing CD15 MFI are plotted on the right y-axis, ***P < 0.0001. 
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since it has been shown that in vitro activated granulocytes 
from healthy donors are also capable of mediating suppres-
sive effects on T cells (36). A precise immunophenotype of the 
GrMDSC referring to different cancer types—including mela-
noma—has still not been defined. Markers that have been 
predominantly used include HLA-DR, CD11b, CD14, CD15 
Fig. 3. Comparison of the GrMDSC frequencies between healthy controls and melanoma patients. (A) Comparison of GrMDSC frequencies 
between healthy controls and all melanoma patients regardless of clinical and pathohistological stage, showing significantly higher values in 
melanoma patients. (B) Comparison of GrMDSC frequencies between healthy controls and melanoma patients in different clinical stages clas-
sified according to the TNM classification, showing significantly higher values in all melanoma stages. GrMDSC are shown as a percentage of 
total leukocytes (mean ± SEM). Mann−Withney test (unpaired, two tailed, **P < 0.01, ***P < 0.001).
Fig. 4. (A) Comparison of GrMDSC frequencies between healthy controls and melanoma patients classified according to AJCC staging for 
melanoma, showing significantly higher values in all melanoma stages. (B) Comparison of GrMDSC frequencies between different AJCC mela-
noma stages showing the highest values in the stage IV, with statistical significance in comparison with IA, IB, IIA and IIB melanoma stages. 
GrMDSC frequencies are shown as a percentage of total leukocytes (mean ± SEM). Student’s t-test (unpaired, two tailed, *P < 0.05, **P < 0.01, 
***P < 0.001; ns, not significant).
Fig. 5. (A) Comparison of GrMDSC frequencies between groups of melanoma patients with and without progression, showing significantly 
higher values in the group of patients with progressive melanoma disease. (B) Comparison of GrMDSC frequencies between groups of patients 
with progressive disease according to their PFI (cut-off value 12 months), showing significantly higher values in the group of patients with the 
PFI shorter than 12 months. GrMDSC frequencies are shown as a percentage of total leukocytes (mean ± SEM). Student’s t-test (unpaired, two 
tailed, *P < 0.05, **P < 0.01). (C) Correlation of GrMDSC frequencies in the peripheral blood of melanoma patients and PFI measured in months, 
showing statistically significant inverse relationship (Spearman’s correlation test).
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and CD33 (5), as well as CD66b and CD16 for additional 
subclassification of GrMDSC (21). Accordingly, we defined 
our GrMDSC as CD11b+CD14−CD15+CD33+ cells within the 
HLA-DR−/low population. However, the presented immunophe-
notype also fits to the phenotype of mature granulocytes (37) 
and carries a risk of losing CD11b− MDSC from analysis (38), 
imposing a careful and highly critical approach to the flow 
cytometric enumeration of GrMDSC, with special emphasis 
on pattern and intensity of surface membrane marker expres-
sion. Potential significance of membrane markers expression 
intensity, in relation to the particular cell subsets function, 
has been shown in animal models. Youn et al. showed that 
the GrMDSC expressed lower levels of CD11b than mature 
granulocytes in different mouse tumor models—including 
melanoma (39). Similarly, Greifenberg et  al. identified two 
subsets of neutrophils with a different CD11b expression in 
the spleens of healthy mice, wherein only the relatively low 
CD11b-expressing cells were found to be immune suppres-
sive, exhibiting characteristics of GrMDSC (40). Our findings 
show lower and inhomogeneous expression of all GrMDSC 
positive markers—including CD11b—relative to mature gran-
ulocytes. We consider that the intensity and pattern of expres-
sion of surface membrane markers are of great importance 
when discussing the phenotype of GrMDSC. In this regard, 
the presence of mature granulocytes in lysed peripheral blood 
samples allows comparison between the two cell populations.
Since the expression of the CD10 molecule in neutrophilic 
granulocytes occurs only in mature forms (37), we used this 
marker to assess the maturity of the GrMDSC and for their 
phenotypical separation from the mature granulocytes. In addi-
tion to the lower SS positioning and inhomogeneous pattern 
of expression of all the positive surface membrane markers 
on the GrMDSC (CD11b, CD15, CD16, CD33, CD45), we pro-
pose the CD10 as one of the useful markers for discrimination 
between GrMDSC (CD10−) and mature granulocytes (CD10+). 
An additional value of CD10 tracking lies in the regulatory role 
of this molecule and its up-regulation upon activation of granu-
locytes by various stimuli, such as GM-CSF, TNF, C5a or formyl-
methionyl-leucyl-phenylalanine (FMLP) (37, 41). Activation of 
granulocytes causes changes in their density leading to altered 
buoyancy and copurification with PBMC on density gradients 
(36, 42). Thus, up-regulation of CD10 on mature activated 
granulocytes allows their flow cytometric separation from CD10 
negative GrMDSC, which also copurify with PBMC. Moreover, 
Sagiv et al. shed a new light on the plasticity of mature neutro-
phils showing that they can change from ‘normal’ high-density 
to low-density neutrophils and vice versa in the peripheral blood 
of tumor-bearing mice and human lung cancer patients (43). 
They showed that the high-density neutrophil fraction (HDN) 
was almost completely composed of mature cells, whereas 
the low-density fraction (LDN) contained two types of granulo-
cytes: immature—presumably the GrMDSC, and mature granu-
locytes—derived from HDN fraction. This finding gives even 
more sense to the monitoring of CD10 expression in low-density 
granulocytes. In addition, Sagiv et al. observed that their LDNs 
contained two subpopulations distinct in size according to for-
ward scatter in flow cytometric analyses. We think it would be 
very interesting to examine whether there are differences in the 
expression of CD10 between the two populations. Unlike us, 
they did not find differences in SS between HDNs and LDNs.
Regarding other markers that are useful for maturity 
assessment, our GrMDSC showed highly inhomogene-
ous expression of CD16 with a wide range of fluorescence 
intensity, revealing the presence of granulocyte precursors 
in different developmental stages within the single GrMDSC 
population. The CD16 molecule is absent from the surface 
of neutrophil precursors in the earliest stages of develop-
ment and appears at the metamyelocyte stage with gradu-
ally increasing expression toward mature neutrophils (37). 
In combination with CD14 and CD15, low and inhomogene-
ous, but still positive expression of CD16 allowed us to dis-
tinguish our CD14−CD15+CD16low/int GrMDSC from monocytes 
(CD14+CD15−/low), eosinophils (CD15+CD16−) and mature 
neutrophils (CD15+CD16high) (37, 44).
As mentioned, our targeted population of HLA-DR−/low 
CD10−CD11b+CD14−CD15+CD16low/intCD33lowCD45lowLin− 
cells copurified with the PBMC on density gradient. Although 
copurification with PBMC, by itself, does not prove immuno-
suppressive capabilities of the GrMDSC, it is in accordance 
with many studies that clearly showed that granulocyte-like 
cells with altered density do exert immunosuppressive activi-
ties (6, 12, 36, 42). Further on, we ascertained significant 
Fig. 6. (A) Comparison of GrMDSC frequencies between the patients with localized melanoma and the patients with metastatic melanoma 
disease, showing significantly higher values in the group of patients with metastatic disease. (B) Comparison of GrMDSC frequencies between 
the groups of melanoma patients with different risk for developing distant metastases and the group of patients within stage IV of melanoma, 
showing significantly higher values in the group of patients within stage IV in comparison with the groups with low and medium risk. The differ-
ence between high-risk group and stage IV melanoma patients was not significant. GrMDSC frequencies are shown as a percentage of total 
leukocytes (mean ± SEM). Student’s t-test (unpaired, two tailed, **P < 0.01, ***P < 0.001; ns, not significant).
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positive correlation of GrMDSC frequencies with ARG1 activ-
ity, IL-5 and NO in the sera of our melanoma patients and a 
very intriguing inverse correlation between CD16 expression 
on GrMDSC and IL-1b, IL-4, IL-5, IL13 and IL-10 (unpublished 
data). These findings are consistent with the immunosup-
pressive activities of the GrMDSC and factors that promote 
their accumulation (32, 42, 45–47).
There are several publications regarding the expansion of 
MDSC in animal models with various solid tumors and, to a 
lesser extent, in human patients with different solid tumors—
including melanoma (9, 10, 48). Our findings confirm that 
there is a significant increase in the MDSC frequency, specifi-
cally GrMDSC, in the peripheral blood of melanoma patients 
compared with healthy individuals. Regardless of the mela-
noma clinical stage and classification method, TNM or AJCC, 
GrMDSC frequencies appeared to be significantly higher in 
melanoma patients, compared with healthy controls. Even the 
patients in stage IA with the smallest tumor burden had a sig-
nificantly increased frequency of GrMDSC in their peripheral 
blood compared with healthy controls, indicating accumu-
lation of these cells as an early event in melanoma devel-
opment. This observation is in agreement with the study of 
Montero et al. (11), though there are studies demonstrating 
enlarged MDSC accumulation only in the later stages in some 
other solid tumors (49) We speculate that the expansion of 
GrMDSC is more common in the early stage of melanoma 
than in other cancer types because of the specific genetic 
background of melanoma cells and higher capacity for pro-
ducing factors involved in MDSC accumulation (50).
An intriguing observation regarding GrMDSC accumulation 
was the disturbed myelopoiesis in our melanoma patients, 
wherein the GrMDSC and the mature granulocytes showed 
a significant inverse relationship despite the fact that the NLR 
did not differ significantly from the healthy controls. This finding 
suggests that the production of the GrMDSC happens at the 
expense of production of mature granulocytes. Nevertheless, 
Sagiv et al. showed that despite a large accumulation of LDGs 
in the peripheral blood of tumor-bearing mice, there was no 
significant reduction of HDNs in the bone marrow (43).
Similar to other investigators (6, 7), we also found that 
melanoma patients in stage IV had highest frequencies of 
GrMDSC in their peripheral blood. We found statistically 
significant differences in GrMDSC frequencies between the 
stage IV and stages IA, IB, IIA and IIB. On the contrary, we 
did not find statistically significant differences in GrMDSC 
frequencies between the stage IV and stages IIC, IIIA, IIIB 
and IIIC. Interestingly, patients with IIC, IIIA, IIIB and IIIC 
melanoma stages, whose GrMDSC frequencies did not dif-
fer significantly from the stage IV melanoma patients, were 
the patients with a high risk for developing distant metasta-
ses (51). This suggests a continuous increase in the num-
ber of GrMDSC with the progression of melanoma from the 
early stage IA to the stage IV. Similarly, Filipazzi et al. showed 
that there is the accumulation of MDSC in the early stage of 
melanoma followed by a gradual increase toward the stage 
IV (52). Our results show that for every subsequent higher 
stage of melanoma, there is a small gradual increase in the 
GrMDSC frequency. Interestingly, we did not find any statis-
tically significant difference in the frequencies of GrMDSC 
when compared stage by stage.
Additionally, we confirmed significantly higher GrMDSC 
frequencies in melanoma patients with an extensive dis-
ease (stages III and IV) compared with those with localized 
disease (stages I and II). Diaz-Montero et al. found signifi-
cantly higher frequencies of MDSC in the peripheral blood 
of patients with advanced melanoma but, unlike us, they 
tested patients in the stage III and stage IV as two separate 
groups (7).
The importance of MDSC and their role in melanoma 
development is well described in mouse models (21) but 
on the contrary, very few studies have been undertaken on 
the subject of melanoma in humans. Although recent stud-
ies confirmed the accumulation of MDSC in the tissue of 
human melanoma in the stages III and IV and highlighted 
the immunosuppressive function of these cells (9, 10, 52), 
the majority of these studies did not compare frequencies 
of GrMDSC separately for each stage in the same patient 
during the progression of their melanoma. An exception 
to the aforementioned is the study of Kimberly et  al., who 
examined the frequency, suppressive function and role of 
multiple MDSC subsets in melanoma patients depending on 
the stage of their disease. Among other findings, Kimberly 
et  al. showed that the frequency of HLA-DR−CD33+CD14− 
MDSC correlated well with an overall survival and disease 
progression and that the high frequency of these cells pre-
dicts a significantly increased risk of disease progression. 
They proposed that these cells could be used as a poten-
tial prognostic biomarker (6). Unfortunately, Kimberly et al. 
were unable to identify the GrMDSC subset of these cells 
due to the loss of a CD15 antigen in the process of blood 
cryopreservation and CD15 is one of the crucial markers for 
this subset (53). One could speculate that Kimberly’s HLA-
DR−CD33+CD14− MDSC could actually be GrMDSC, which 
lost their surface CD15 during cryopreservation. We man-
aged to overcome this limitation by using fresh peripheral 
blood samples instead of frozen and consequently, we were 
able to detect CD14−CD15+ MDSCs (GrMDSC) in all tested 
patients and controls. Our patients who had the progression 
of their melanoma had significantly higher GrMDSC frequen-
cies compared to those with a stable disease. Moreover, we 
recorded the PFI for each patient with a progressive disease 
and then correlated PFI with the frequencies of GrMDSC in 
the peripheral blood. There was a statistically significant 
inverse correlation between the GrMDSC frequencies and 
the time for progression. Thus, we found that the greater the 
frequency of GrMDSC, the shorter the period of time to pro-
gression. In addition, we found that patients who on follow-up 
progressed within the first 12 months had significantly higher 
frequencies of GrMDSC in the peripheral blood compared 
with patients whose PFI was longer than 12 months.
Conclusion
Although the technique with fresh lysed blood was commonly 
available, it was not frequently utilized by previous research-
ers interested in MDSC. We spotted the advantage of the 
lysed fresh blood over frozen, especially for thermo-sensitive 
antigens like CD15, which are essential for immunophenotyp-
ing of the GrMDSC subset. A careful and critical approach to 
a pattern of surface marker expression and use of CD10 and 
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CD16 staining are of great importance in phenotypic sepa-
ration between GrMDSC and mature granulocytes. The key 
result in this study is the finding that GrMDSC was the pre-
dominant subset of MDSC detected in melanoma patients. We 
confirmed that GrMDSC do accumulate early in the peripheral 
blood of melanoma patients and their frequencies are signifi-
cantly elevated in melanoma patients compared with healthy 
individuals. The frequencies of these cells correlate well with 
the clinical stage and the spread of the disease. The increase 
in the GrMDSC frequency correlates well with a progression 
of the disease and could be considered a potential predictive 
biomarker of high-risk melanoma cases that are more likely 
to have a shorter PFI. Disturbed myelopoiesis in melanoma 
patients could contribute to the impaired host defense not only 
by production of suppressive myeloid cells but also with the 
decreased production of the cells of the first line of defense—
mature granulocytes. Further investigations of humoral factors 
involved in the differentiation and expansion of the GrMDSC 
subset in the early stage of melanoma are required.
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